Sunday, 26 January 2020

J&J commits $500M investment to end TB, HIV

08 October 2019 | News

To accelerate global efforts to eliminate HIV and tuberculosis (TB) by 2030.

Image credit- shuttershock.com

Image credit- shuttershock.com

Johnson & Johnson has announced that it has committed to ensuring more than $500 million is dedicated to world class research & development and delivery programs over the next four years to accelerate global efforts to eliminate HIV and tuberculosis (TB) by 2030. 

HIV

The Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have been committed to the fight against HIV for more than 25 years. Over this time, the Company has introduced eight transformational HIV medicines – including three antiviral agents and five combination products developed in partnership – which have helped to transform HIV/AIDS from a death sentence  into a chronic, manageable disease, allowing millions of people living with HIV to lead near normal lives.

As part of the $500 million investment, Janssen will continue to advance an investigational mosaic-based vaccine regimen to prevent HIV together with a consortium of partners.  An ongoing efficacy trial (Imbokodo) in 2,600 women in Southern Africa is fully enrolled. A second efficacy trial (Mosaico) is about to commence in North AmericaSouth America and Europe with 3,800 men who have sex with men and transgender individuals.

In partnership with ViiV Healthcare, Janssen is also investigating a long-acting injectable HIV treatment regimen that could be administered to patients once every two months.  This regimen, if approved, could potentially reduce HIV treatment for some patients to just twelve or even six injection visits per year to keep the virus under control, instead of a daily oral treatment taken 365 times per year.

Tuberculosis

In 2012, Janssen introduced bedaquiline, which was the first TB medicine with a novel mechanism of action in nearly half a century. Since then, the Company has provided more than 145,000 courses of treatment for multidrug-resistant TB (MDR-TB) patients in 131 countries, including through a four-year donation program that operated in the 2015-2019 period in partnership with the U.S. Agency for International Development and JSC Pharmstandard.

At the United Nations High-Level Meeting on Tuberculosis in September 2018, Johnson & Johnson announced a comprehensive 10-year initiative to support ending the TB epidemic by 2030, which builds on our current Health for Humanity 2020 TB Goal.  With the goal of saving an estimated 1.8 million lives and preventing 12 million new TB infections in the next decade, Johnson & Johnson is working with partners to improve detection of undiagnosed cases of TB, broaden access to bedaquiline, and accelerate research & development (R&D) to discover next-generation TB treatments.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is 2020 demanding timely action of technology adoption in healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls